Journal
FASEB JOURNAL
Volume 34, Issue 1, Pages 208-221Publisher
FEDERATION AMER SOC EXP BIOL
DOI: 10.1096/fj.201901537R
Keywords
anti-inflammation; ginsenoside Rg3; inflammasome; NLRP3 inflammasome
Categories
Funding
- Zhejiang Provincial Natural Science Foundation [LY18C180001, LQ15C180002]
- National Natural Science Foundation of China [31502034]
- Fundamental Research Funds for the Central Universities [2018QNA6032]
Ask authors/readers for more resources
Ginsenoside Rg3 is one of the main constituents of Panax ginseng. Compelling evidence has demonstrated that ginsenoside Rg3 is capable of inhibiting inflammation. However, the mechanism mediating its anti-inflammatory effects remain unclear. Here we show that ginsenoside Rg3 blocks IL-1 beta secretion and caspase-1 activation through inhibiting LPS priming and the NLRP3 inflammasome activation in human and mouse macrophages. Rg3 specifically inhibits activation of NLRP3 but not the NLRC4 or AIM2 inflammasomes. In addition, Rg3 has no effect on upstream regulation of NLRP3 inflammasome, such as K+ efflux, ROS production, or mitochondrial membrane potential. Mechanistically, Rg3 abrogates NEK7-NLRP3 interaction, and subsequently inhibits NLRP3-ASC interaction, ASC oligomerization, and speckle formation. More importantly, Rg3 can reduce IL-1 beta secretion induced by LPS in mice and protect mice from lethal endotoxic shock. Thus, our findings reveal an anti-inflammatory mechanism for Rg3 and suggest its potential use in NLRP3-driven diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available